They propose, unlike Reiterer et al., that hyperglycemia in severe COVID-19 patients is due to both compromised insulin secretion and decreased insulin sensitivity; however, this inference could have been influenced by their inclusion of diabetic patients who already have compromised insulin secretion. The gene discussed is INS; the disease is COVID-19.